Democrats want to overhaul Warp Speed. But if Biden wins, should he?
Democrats have called for the ouster of the Warp Speed chief and an overhaul of the program. But if Biden wins, should he upend it?
Related Articles
Pharmalittle: We’re reading about MDMA for PTSD, a CRISPR treatment for blindness, and more
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
Pharmalittle: We’re reading about FTC reviewing Novo-Catalent deal, Amneal opioid settlement, and more
The FTC wants more information on a $16.5 million deal in which Novo Nordisk’s parent company would purchase Catalent, a contract drug manufacturer.
Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
Gilead gets a boost from California court in a case over slow-walking an HIV drug
The move by the California Supreme Court to review the case is seen as “very important,” according Evercore ISI analyst Umer Raffat.
Gilead gets a boost from California court in a case over slow-walking an HIV drug
The move by the California Supreme Court to review the case is seen as “very important,” according Evercore ISI analyst Umer Raffat.
Pharmalittle: We’re reading about Wegovy and Ozempic sales, rising pharma layoffs, and more
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to…
Pharmalittle: We’re reading about FTC fighting ‘junk’ patents, Pfizer direct-to-consumer plans, and more
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.
‘Skinny labels’ on generic medicines saved Medicare $15 billion over a recent six-year period
A controversial provision of a federal law designed to speed copycat drugs to market and foster competition saved Medicare Part D nearly $15 billion from
FTC issues warnings on ‘junk’ patent listings for Ozempic and other drugs
“By filing bogus patent listings, pharma companies block competition and inflate the cost of prescription drugs,” said FTC Chair Lina Khan.
Pharmalittle: We’re reading about a Medicare price-negotiation ruling, pharma’s slipping reputation, and more
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.